As a Free StocksGuide user, you can view scores for all 7,003 stocks worldwide.
22 Analysts have issued a Immunovant Inc forecast:
22 Analysts have issued a Immunovant Inc forecast:
Jun '25 |
+/-
%
|
||
Revenue | - - |
-
|
|
Gross Profit | - - |
-
|
|
EBITDA | -471 -471 |
58%
58%
|
EBIT (Operating Income) EBIT | -471 -471 |
58%
58%
|
Net Profit | -447 -447 |
64%
64%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Immunovant, Inc. is a clinical-stage biopharmaceutical company. It focuses on enabling normal lives for patients with autoimmune diseases. The company was founded in 2018 and is headquartered in New York, NY.
Head office | United States |
CEO | Eric Venker |
Employees | 207 |
Founded | 2018 |
Website | immunovant.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.